EUVIMEDEUVIMED entdecken
Crossref

Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin

Alan N Gordon

European Oncology & Haematology · 2005

DOI: 10.17925/eoh.2005.0.0.83 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Oncology & Haematology, 2005. Verfasst von Alan N Gordon. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gordon, A. N. (2005). Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin. European Oncology & Haematology. https://doi.org/10.17925/eoh.2005.0.0.83

Vancouver

Gordon AN. Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin. European Oncology & Haematology. 2005. doi:10.17925/eoh.2005.0.0.83

BibTeX
@article{Gordon2005,
  author = {Gordon, Alan N},
  title = {Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin},
  journal = {European Oncology & Haematology},
  year = {2005},
  doi = {10.17925/eoh.2005.0.0.83}
}
Kostenlos starten →